Aridis Pharmaceuticals (NASDAQ:ARDS) Announces Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Share on StockTwits

Aridis Pharmaceuticals (NASDAQ:ARDS) posted its quarterly earnings results on Monday. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.19), Bloomberg Earnings reports. Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%.

ARDS opened at $8.15 on Wednesday. The stock’s 50 day moving average is $9.64. Aridis Pharmaceuticals has a 1 year low of $6.91 and a 1 year high of $13.85. The company has a market cap of $66.08 million and a price-to-earnings ratio of -1.16.

ARDS has been the topic of several recent research reports. ValuEngine upgraded Aridis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Maxim Group restated a “buy” rating on shares of Aridis Pharmaceuticals in a research report on Wednesday, July 31st. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, Northland Securities restated a “buy” rating and set a $40.00 price target on shares of Aridis Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $27.50.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Recommended Story: Diversification Important in Investing

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Becton Dickinson and Co  Shares Sold by Western Wealth Management LLC
Becton Dickinson and Co Shares Sold by Western Wealth Management LLC
Eaton Co. PLC  Stake Reduced by Western Wealth Management LLC
Eaton Co. PLC Stake Reduced by Western Wealth Management LLC
Western Wealth Management LLC Has $382,000 Stake in iShares US Financials ETF
Western Wealth Management LLC Has $382,000 Stake in iShares US Financials ETF
Western Wealth Management LLC Invests $412,000 in Centurylink Inc
Western Wealth Management LLC Invests $412,000 in Centurylink Inc
Western Wealth Management LLC Sells 3,769 Shares of iShares Morningstar Mid-Cap Growth ETF
Western Wealth Management LLC Sells 3,769 Shares of iShares Morningstar Mid-Cap Growth ETF
Western Wealth Management LLC Sells 510 Shares of iShares Short Maturity Bond ETF
Western Wealth Management LLC Sells 510 Shares of iShares Short Maturity Bond ETF


© 2006-2019 Ticker Report